Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1990 1
1991 1
1993 1
1995 1
1996 5
1997 4
1998 8
1999 6
2000 3
2001 8
2002 9
2003 17
2004 9
2005 16
2006 20
2007 9
2008 9
2009 8
2010 7
2011 5
2012 4
2013 2
2014 2
2015 1
2018 1
2020 1
2021 1
2022 1
2023 5
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

150 results

Results by year

Filters applied: . Clear all
Page 1
A practical update on the use of bortezomib in the management of multiple myeloma.
San Miguel J, Bladé J, Boccadoro M, Cavenagh J, Glasmacher A, Jagannath S, Lonial S, Orlowski RZ, Sonneveld P, Ludwig H. San Miguel J, et al. Among authors: glasmacher a. Oncologist. 2006 Jan;11(1):51-61. doi: 10.1634/theoncologist.11-1-51. Oncologist. 2006. PMID: 16401713 Free article. Review.
Bisphosphonates in multiple myeloma: a network meta-analysis.
Mhaskar R, Redzepovic J, Wheatley K, Clark OA, Miladinovic B, Glasmacher A, Kumar A, Djulbegovic B. Mhaskar R, et al. Among authors: glasmacher a. Cochrane Database Syst Rev. 2012 May 16;(5):CD003188. doi: 10.1002/14651858.CD003188.pub3. Cochrane Database Syst Rev. 2012. PMID: 22592688 Updated. Review.
A systematic review of phase II trials of thalidomide/dexamethasone combination therapy in patients with relapsed or refractory multiple myeloma.
von Lilienfeld-Toal M, Hahn-Ast C, Furkert K, Hoffmann F, Naumann R, Bargou R, Cook G, Glasmacher A. von Lilienfeld-Toal M, et al. Among authors: glasmacher a. Eur J Haematol. 2008 Oct;81(4):247-52. doi: 10.1111/j.1600-0609.2008.01121.x. Epub 2008 Jul 10. Eur J Haematol. 2008. PMID: 18637031 Free PMC article. Review.
Bisphosphonates in multiple myeloma.
Djulbegovic B, Wheatley K, Ross J, Clark O, Bos G, Goldschmidt H, Cremer F, Alsina M, Glasmacher A. Djulbegovic B, et al. Among authors: glasmacher a. Cochrane Database Syst Rev. 2002;(3):CD003188. doi: 10.1002/14651858.CD003188. Cochrane Database Syst Rev. 2002. PMID: 12137679 Updated. Review.
Thalidomide in multiple myeloma.
Moehler TM, Hillengass J, Glasmacher A, Goldschmidt H. Moehler TM, et al. Among authors: glasmacher a. Curr Pharm Biotechnol. 2006 Dec;7(6):431-40. doi: 10.2174/138920106779116919. Curr Pharm Biotechnol. 2006. PMID: 17168659 Review.
Bisphosphonates in multiple myeloma.
Mhaskar R, Redzepovic J, Wheatley K, Clark OA, Miladinovic B, Glasmacher A, Kumar A, Djulbegovic B. Mhaskar R, et al. Among authors: glasmacher a. Cochrane Database Syst Rev. 2010 Mar 17;(3):CD003188. doi: 10.1002/14651858.CD003188.pub2. Cochrane Database Syst Rev. 2010. PMID: 20238320 Updated. Review.
150 results